HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Doxycycline attenuates cisplatin-induced acute kidney injury through pleiotropic effects.

Abstract
Cisplatin (CDDP) is a widely-used chemotherapeutic drug for solid tumors, but its nephrotoxicity is a major dose-limiting factor. Doxycycline (Dox) is a tetracycline antibiotic that has been commonly used in a variety of infections. Dox has been shown to possess several other properties, including antitumor, anti-inflammatory, antioxidative, and matrix metalloproteinase (MMP)-inhibiting actions. We, therefore, investigated whether Dox exerts renoprotective effects in CDDP-induced acute kidney injury (AKI). Twelve-week-old male C57BL/6J mice were divided into the following groups: 1) control, 2) Dox (2 mg/ml in drinking water), 3) CDDP (25 mg/kg body weight, intraperitoneally), and 4) CDDP+Dox. After seven days of pretreatment with Dox, CDDP was administered and the animals were killed at day 1 or day 3. We evaluated renal function along with renal histological damage, inflammation, oxidative stress, and apoptosis. MMP and serine protease activities in the kidney tissues were assessed using zymography. Administration of CDDP exhibited renal dysfunction and caused histological damage predominantly in the proximal tubules. Dox did not affect either expression of CDDP transporters or the accumulation of CDDP in renal tissues; however, it significantly ameliorated renal dysfunction and histological changes together with reduced detrimental responses, such as oxidative stress and inflammation in the kidneys. Furthermore, Dox inhibited the activity of MMP-2 and MMP-9, as well as serine proteases in the kidney tissues. Finally, Dox markedly mitigated apoptosis in renal tubules. Thus, Dox ameliorated CDDP-induced AKI through its pleiotropic effects. Our results suggest that Dox may become a novel strategy for the prevention of CDDP-induced AKI in humans.
AuthorsTerumasa Nakagawa, Yutaka Kakizoe, Yasunobu Iwata, Yoshikazu Miyasato, Teruhiko Mizumoto, Masataka Adachi, Yuichiro Izumi, Takashige Kuwabara, Naoki Suenaga, Yuki Narita, Hirofumi Jono, Hideyuki Saito, Kenichiro Kitamura, Masashi Mukoyama
JournalAmerican journal of physiology. Renal physiology (Am J Physiol Renal Physiol) Vol. 315 Issue 5 Pg. F1347-F1357 (11 01 2018) ISSN: 1522-1466 [Electronic] United States
PMID30043627 (Publication Type: Journal Article)
Chemical References
  • Anti-Inflammatory Agents
  • Antioxidants
  • Inflammation Mediators
  • Matrix Metalloproteinase Inhibitors
  • Protective Agents
  • Reactive Oxygen Species
  • Serine Proteinase Inhibitors
  • Serine Proteases
  • Matrix Metalloproteinase 2
  • Mmp2 protein, mouse
  • Matrix Metalloproteinase 9
  • Mmp9 protein, mouse
  • Doxycycline
  • Cisplatin
Topics
  • Acute Kidney Injury (chemically induced, metabolism, pathology, prevention & control)
  • Animals
  • Anti-Inflammatory Agents (pharmacology)
  • Antioxidants (pharmacology)
  • Apoptosis (drug effects)
  • Cisplatin
  • Cytoprotection
  • Disease Models, Animal
  • Doxycycline (pharmacology)
  • Inflammation Mediators (metabolism)
  • Kidney (drug effects, metabolism, pathology)
  • Male
  • Matrix Metalloproteinase 2 (metabolism)
  • Matrix Metalloproteinase 9 (metabolism)
  • Matrix Metalloproteinase Inhibitors (pharmacology)
  • Mice, Inbred C57BL
  • Oxidative Stress (drug effects)
  • Protective Agents (pharmacology)
  • Reactive Oxygen Species (metabolism)
  • Serine Proteases (metabolism)
  • Serine Proteinase Inhibitors (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: